FindTrial
Sign In

A Comparison Of Dexmedetomidine And Lignocaine In Managing The Intraocular Pressure And Heamodynamic Changes Post Suxamethonium Administration, Laryngoscopy, And Tracheal Intubation In Cancer Surgeries.

A Comparitive Evaluation Of Intravenous Dexmedetomidine And Intravenous Lignocaine In Attenuating The Rise In Intraocular Pressure And Heamodynamic Response Following Administration Of Suxamethonium, Laryngoscopy And Endotracheal Intubation In Oncological Surgeries. - IOP

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/06/088785
Enrollment
100
Registered
2025-06-13
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

Intervention1: Dexmedetomidine injection: Patients will receive 0.5mcg/kg IV dexmedetomidine in 10 ml sterile water, over 10 min prior to induction Control Intervention1: Lignocaine injection: Patient

Sponsors

Dr. Anjana Vinod
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged between 18 and 65 years. (and) Patients belonging to ASA physical status grade 1 and 2. (and) Patients consenting for study.

Exclusion criteria

Exclusion criteria: Patient s refusal (or) Patients with severe cardiac, respiratory and renal disease. (or) Patients with known neurological disorder. (or) Patients with preexisting ocular diseases or history of eye surgery. (or) Pregnant or breastfeeding females. (or) Known allergy or contraindications to either lignocaine or dexmedetomidine.

Design outcomes

Primary

MeasureTime frame
To compare the effect of intravenous dexmedetomidine and intravenous lignocaine for attenuating IOP and hemodynamic response after suxamethonium administration, laryngoscopy and intubationTimepoint: Baseline values, pre-induction, post-induction (1 minute, 3 minutes, 5 minutes)—

Secondary

MeasureTime frame
To study any adverse effects of intravenous dexmedetomidine and intravenous lignocaineTimepoint: Intra-operative and post-operative period (upto 24 hours)—

Countries

India

Contacts

Public ContactDr Namrata Ranganath

Kidwai Memorial Institute of Oncology

namrang@gmail.com9880642830

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026